Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]

Detalles Bibliográficos
Autores principales: Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929237/
https://www.ncbi.nlm.nih.gov/pubmed/34099371
http://dx.doi.org/10.1016/j.annonc.2021.05.797
_version_ 1784670818996846592
author Jhaveri, K.L.
Wang, X.V.
Makker, V.
Luoh, S.-W.
Mitchell, E.P.
Zwiebel, J.A.
Sharon, E.
Gray, R.J.
Li, S.
McShane, L.M.
Rubinstein, L.V.
Patton, D.
Williams, P.M.
Hamilton, S.R.
Conley, B.A.
Arteaga, C.L.
Harris, L.N.
O’Dwyer, P.J.
Chen, A.P.
Flaherty, K.T.
author_facet Jhaveri, K.L.
Wang, X.V.
Makker, V.
Luoh, S.-W.
Mitchell, E.P.
Zwiebel, J.A.
Sharon, E.
Gray, R.J.
Li, S.
McShane, L.M.
Rubinstein, L.V.
Patton, D.
Williams, P.M.
Hamilton, S.R.
Conley, B.A.
Arteaga, C.L.
Harris, L.N.
O’Dwyer, P.J.
Chen, A.P.
Flaherty, K.T.
author_sort Jhaveri, K.L.
collection PubMed
description
format Online
Article
Text
id pubmed-8929237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89292372022-03-25 Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] Jhaveri, K.L. Wang, X.V. Makker, V. Luoh, S.-W. Mitchell, E.P. Zwiebel, J.A. Sharon, E. Gray, R.J. Li, S. McShane, L.M. Rubinstein, L.V. Patton, D. Williams, P.M. Hamilton, S.R. Conley, B.A. Arteaga, C.L. Harris, L.N. O’Dwyer, P.J. Chen, A.P. Flaherty, K.T. Ann Oncol Corrigendum Oxford University Press 2021-08 2021-06-05 /pmc/articles/PMC8929237/ /pubmed/34099371 http://dx.doi.org/10.1016/j.annonc.2021.05.797 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Corrigendum
Jhaveri, K.L.
Wang, X.V.
Makker, V.
Luoh, S.-W.
Mitchell, E.P.
Zwiebel, J.A.
Sharon, E.
Gray, R.J.
Li, S.
McShane, L.M.
Rubinstein, L.V.
Patton, D.
Williams, P.M.
Hamilton, S.R.
Conley, B.A.
Arteaga, C.L.
Harris, L.N.
O’Dwyer, P.J.
Chen, A.P.
Flaherty, K.T.
Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title_full Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title_fullStr Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title_full_unstemmed Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title_short Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
title_sort corrigendum to ‘ado-trastuzumab emtansine (t-dm1) in patients with her2-amplified tumors excluding breast and gastric/gastroesophageal junction (gej) adenocarcinomas: results from the nci-match trial (eay131) subprotocol q': [annals of oncology 30 (2019) 1821–1830]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929237/
https://www.ncbi.nlm.nih.gov/pubmed/34099371
http://dx.doi.org/10.1016/j.annonc.2021.05.797
work_keys_str_mv AT jhaverikl corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT wangxv corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT makkerv corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT luohsw corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT mitchellep corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT zwiebelja corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT sharone corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT grayrj corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT lis corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT mcshanelm corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT rubinsteinlv corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT pattond corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT williamspm corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT hamiltonsr corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT conleyba corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT arteagacl corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT harrisln corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT odwyerpj corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT chenap corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830
AT flahertykt corrigendumtoadotrastuzumabemtansinetdm1inpatientswithher2amplifiedtumorsexcludingbreastandgastricgastroesophagealjunctiongejadenocarcinomasresultsfromthencimatchtrialeay131subprotocolqannalsofoncology30201918211830

Ejemplares similares